Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo

European Journal of Clinical Investigation

Volumn 32, Issue SUPPL. 1, 2002, Pages 9-16

  Rooyakkers, T M ^a   Stroes, E S G ^a   Kooistra, M P ^b   Van Faassen, E E ^c   Hider, R C ^d   Rabelink, T J ^a   Marx, J J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Dianet Foundation   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Endothelial function; Ferric saccharate; Flow mediated dilatation; Nitric oxide; Oxygen radicals; Superoxide

Indexed keywords

IRON; IRON BINDING PROTEIN; IRON SACCHARATE; OXYGEN RADICAL; SODIUM CHLORIDE; FERRIC ION; FERRIC OXIDE, SACCHARATED; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

ARTICLE; BLOOD SAMPLING; DRUG EFFECT; ELECTRON SPIN RESONANCE; ENDOTHELIUM; ENDOTHELIUM LESION; HUMAN; IN VIVO STUDY; INTRAVASCULAR ULTRASOUND; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; VASODILATATION; ADULT; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; SMOKING; VASCULAR ENDOTHELIUM;

ADULT; ENDOTHELIUM, VASCULAR; FERRIC COMPOUNDS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; MALE; NITRIC OXIDE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SMOKING; VASODILATION;

EID: 0036515321     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.0320s1009.x     Document Type: Article

References (42)

1. Kooistra MP, van Es A, Struyvenberg A, Marx JJ. Iron metabolism in patients with anaemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 1991;79:634-9.
2. Housse AA, Pham B, Pagye DE. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. Nephrol Dial Transplant 1998;13:1763-9.
3. Kooistra MP, Marx JJM. The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients. Nephrol Dial Transplant 1998;13:2578-84.
4. Kooistra MP. Erythropoietin, iron, thrombosis: aspects of recombinant human erythropoietin treatment in dialysis patients. Thesis: University Utrecht Addix: Wijk bij duurstede, The Netherlands 1998.
5. Gutteridge JMC, Halliwell B. Iron and oxygen: a dangerous mixture. Chapter 4. In: Ponka P, Schulman HM, Woodwroth RC, editors. Iron Transport and Storage. Boca Raton, FL: CRC Press; 1990, pp. 95-108.
6. Moncada S, Higgs A. The L-arginine - nitric oxide pathway. New Engl J Med 1993;329:2002-11.
7. Gimbrone MA. Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis. Am J Cardiol 1995;75:67b-70b.
8. Luscher TF. The endothelium as target and mediator of cardiovascular disease. Eur J Clin Invest 1993;23:670-85.
9. Wever RPM, Stroes ESG, Rabelink TJ. Nitric oxide and hypercholesterolemia; a matter of oxidation and reduction. Atherosclerosis. 1998;137 (Suppl.):S51-60.
10. Darley Usmar V, Halliwell B. Blood radicals: reactive nitrogen species, reactive oxygen species, transition metal ions, and the vascular system. Pharm Res 1996;13:649-62.
11. Hijmering ML, Stroes ESG, Pasterkamp G, Sierevogel M, Banga JD, Rabelink TJ. Variability of flow mediated dilation. Atherosclerosis 2001;157,2:369-73.
12. Wilmink H, Stroes ESG, Gerritsen W, Wever R, Banga DJ, Erkelens DW, et al. Effect of folic acid on post-prandial endothelial dysfunction. Arterioscler Thromb Vasc Biol 2000;20:185-8.
13. Joannides R, Haefeli WE, Under L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow mediated dilation of peripheral conduit arteries in vivo. Circulation 1995;91:1314-9.
14. Singh S, Hider RC, Porter JB. A direct method for quantification of non-transferrin bound iron. Analytical Biochem 1990;186:320-3.
15. Mottley C, Mason RP. Nitroxide radical adducts in biology: chemistry, applications and pitfalls. In: Berliner L, Reuben J, editors. Biological magnetic resonance. Vol. 8. New York: Oxford University Press; 1989, pp. 489-545.
16. Mason RP, Knecht KT. In vivo detection of radical adducts by electron spin resonance. Meth Enzymol 1994;233:111-7.
17. Esposito BP, Breuer W, Slotki I and Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur. J. Clin Inv. 2002;32 (Suppl. 1):42-50.
18. Yuan XM, Brunk UT. Iron and LDL-oxidation in atherogenesis. APMIS 1998;106:825-42.
19. Voest EE, Vreugdenhill G, Marx JJM. Iron-chelating agents in non-iron overload conditions. Ann Intern Med 1994;12:490-9.
20. Corti M, Gaziano M, Hennekens CH. Iron status and risk of cardiovascular disease. Ann Epidemiol 1997;7:62-8.
21. Tuomainen T-K, Punnonen K, Nyyssonen K, Salonen JT. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 1998;97:1461-6.
22. Roest M, van der Schouw YT, de Valk BD, Marx JJM, Tempelman MJ, de Groot PG, et al. Heterozygosity for the hereditary hemochromatosis gene is associated with cardiovascular mortality in women. Circulation 1999;100: 1268-73.
23. Tuomainen TP, Kontula K, Nyssonen K, Lakka TA, Helio T, Salonen JT. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: a prospective cohort study in men in eastern Finland. Circulation 1999;100:1260-3.
24. Motoyama T, Kawano H, Kugiyama K, Hirashima O, Ohgushi M, Yushimura M, et al. Endothelium dependent vasodilation in the brachial artery is impaired in smokers: effect of vitamin C. Am J Physiol 1997;273(4 part 2):H1644-50.
25. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999;14:2680-7.
26. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 1994;9:1136-42.
27. Schrander-van de Meer AM, van Saase JLCM, Roodvoets AP, van Dorp WT. Mortality in patients receiving renal replacement therapy. A single center study. Clin Nephrol 1995;43:174-9.
28. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
29. Neunteufl T, Heher S, Katzenschlager R, Wolfl G, Kostner K, Maurer G, et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000;86:207-10.
30. Schroeder S, Enderle MD, Ossen R, Meisner C, Baumbach A, Pfohl M, et al. Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging. Am Heart J 1999;138:731-9.
31. Vogel RA, Corretti M, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 1997;79:350-4.
32. Akbari CM, Saouf R, Barnhill DF, Newman PA, LoGerfo FW, Veves A. Endothelium-dependent vasodilation is impaired in both microcirculation and macrocirculation during acute hyperglycemia. J Vasc Surg 1998;28:687-94.
33. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999;34:146-54.
34. Shige H, Ishikawa T, Suzukawa M, Ito T, Nakajima K, Higashi K, et al. Endothelium-dependent flow-mediated vasodilation in the post-prandial state in type 2 diabetes mellitus. Am J Cardiol 1999;84:1272-4.
35. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996;27:567-74.
36. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia. An effect reversible with vitamin C therapy. Circulation 1999;99:1156-60.
37. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Endothelial dysfunction by acute hyperhomocyst (e) inaemia: restoration by folic acid. Clin Sci 1999;96:235-9.
38. Chao CL, Chien KL, Lee YT. Effect of short term vitamin (folic acid, vitamins B6 and B12) administration on endothelial dysfunction induced by post-methionine load hyperhomocysteinemia. Am J Cardiol 1999;84:1359-61,A-8.
39. Guldener C, Lambert J, Janssen MJFM, Steyn M, Donker AJ, Stehouwer CD. Endothelium-dependent vasodilation and distensibility of large arteries in chronic hemodialysis patients. Nephrol Dial Transplant 1997;12 (Suppl 2):14-8.
40. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Abnormalities of endothelial function in patients with predialysis renal failure. Heart 2000;83:205-9.
41. Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999;10:594-600.
42. Xiao S, Schmidt RJ, Baylis C. Plasma from ESRD patients inhibits nitric oxide synthase activity in cultured human and bovine endothelial cells. Acta Physiol Scand 2000;168:175-9.